Tolerability to β-blocker therapy among heart failure patients in clinical practice

Journal of Cardiac Failure

Volumn 9, Issue 3, 2003, Pages 203-209

  Butler, Javed ^a,b   Khadim, Ghazanfar ^a   Belue, Rhonda ^a   Chomsky, Don ^a   Dittus, Robert S ^a   Griffin, Marie ^b   Wilson, John R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adrenergic receptor antagonists; Adverse effects

Indexed keywords

BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ETACRYNIC ACID; FOSINOPRIL; FUROSEMIDE; GLUCOSE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; QUINAPRIL; TORASEMIDE; UNCLASSIFIED DRUG; VALSARTAN;

ADULT; AGED; ANOREXIA; ARTICLE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPOTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VERTIGO; WEIGHT GAIN;

EID: 0037937450     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2003.34     Document Type: Article

References (22)

1. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
2. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
3. The Cardiac Insufficiency Bisoprolol Study II: a randomized trial. Lancet 1999;353:9-13.
4. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure. Lancet 1999;353:2001-7.
5. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR, et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000;36:2072-80.
6. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction. JAMA 1998;280:623-9.
7. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31.
8. Gottlieb SS, Fisher ML, Kjekshus J, Deedwania P, Gullestad L, Vitovec J, et al. Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure. Circulation 2002;105:1182-8.
9. The Beta-Blocker Evaluation of Survival Trial. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-67.
10. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-7.
11. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
12. Sanderson JE, Chan SK, Yip G, Yeung LY, Chan KW, Raymond K, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34:1522-8.
13. Farrell MH, Foody JM, Krumholz HM. Beta-blockers in heart failure: clinical applications. JAMA 2002;287:890-7.
14. Stevenson LW. Beta-blockers for stable heart failure. N Engl J Med 2002;346:1346-7.
15. Hunt HA, Baker DW, Chin MH, Cinquegrani MP, Feldmann AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adults. Circulation 2001;104:2996-3007.
16. Heart Failure Society of America guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction. J Card Failure 1999;5:357-382.
17. Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997;30:518-26.
18. Hanumanthu S, Butler J, Chomsky D, Davis S, Wilson JR. Effect of a heart failure program on hospitalization frequency and exercise tolerance. Circulation 1997;96:2842-8.
19. Fonarow GC, Stevenson LW, Walden JA, Livingston NA, Steimle AE, Hamilton MA, et al. Impact of a comprehensive heart failure management program on hospital read-mission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997;30:725-32.
20. Ansari M, Alexander M, Tutar A, Bello D, Massie BM. Cardiology participation improves outcomes in patients with new-onset heart failure in the outpatient setting. J Am Coll Cardiol 2003;41:62-8.
21. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002;21:1290-5.
22. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New Engl J Med 1996;335:1107-14.